-transparent.png){kind=logo}
The expression of progenitor cell associated antigen CD34 was investigated in cells from 28 patients with chronic myeloid leukemia (CML). The CD34 positivity varied from 0-26% in patients with chronic phases CML (n = 17); from 6-64% in patients with accelerated phase CML (n = 4); and from 27-97% in the patients with blastic crisis of CML (n = 8). The difference in CD34 positivity between chronic (mean 10.1 +/- 2.3%), accelerated (37.7 +/- 13.3%) and blastic (58.0 +/- 7.3%) phases of CML is statistically significant (p less than 0.05), however, the number of patients studied, especially in accelerated and blastic phases is very small. There was no difference in the CD34 positivity of the cells in the peripheral blood and in the bone marrow. CD34 positivity was higher in patients with chronic phase CML at diagnosis (untreated patients) than in those who were studied during treatment. The possible importance of serially studying CD34 positivity in patients with CML is discussed in the paper.
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
January 1989,
Leukemia research,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
September 1996,
Bone marrow transplantation,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
April 2008,
Stem cells (Dayton, Ohio),
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
December 2023,
Cells,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
February 1993,
Journal of cutaneous pathology,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
July 1991,
American journal of clinical pathology,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
November 2002,
Proceedings of the National Academy of Sciences of the United States of America,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
October 2005,
Zhongguo shi yan xue ye xue za zhi,
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
September 2021,
Stem cells (Dayton, Ohio),
S Banavali, and
F Silvestri, and
B Hulette, and
P Hurtubise, and
A Srivastava, and
C I Civin, and
H D Preisler
November 2022,
Bone marrow transplantation,
